hrp0095p1-350 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Phenotypic characteristics of a cohort of patients with Septo-Optic Dysplasia followed in a Tertiary Centre.

Ardila Santos Sandra , Ciaccio Marta , Isabel Di Palma Maria

Introduction: Septo-optic dysplasia (SOD) is an uncommon, highly heterogeneous entity of multifactorial etiology, consisting in the association of 2 or more of the following characteristics: ophthalmological abnormalities [most frequently optic nerve hypoplasia (ONH)], midline brain abnormalities [such as aplasia/hypoplasia of the septum pellucidum (SP) and/or corpus callosum (CC)] and variable degree of hypotalamo-pituitary insufficiency (HPI)<p class="ab...

hrp0095p2-48 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

An Unusual Case of Rickets and Anemia Due To Severe Nutritional Deficiency in A Child of Non-Caucasian Ethnicity

Urbano Flavia , Chiarito Mariangela , Moscogiuri Luigi , Felicia Faienza Maria

Background: Rickets is a disease due to a reduced mineralization of the rapidly growing bones (skull, ribs, wrists, knees, ankles) with consequent accumulation of non-mineralized bone matrix, called osteoid tissue. The most frequent cause of rickets is vitamin D and/or calcium deficiency caused by reduced sun exposure, inadequate dietary intake or malabsorption (nutritional rickets).Clinical history: R., a 1 year and 6 m...

hrp0095p2-50 | Diabetes and Insulin | ESPE2022

Inhaled glucagon, a new well-accepted therapeutic tool in pediatrics

Diez-Lopez Ignacio , Sarasua-Miranda Ainhoa , José Espina-Diez Maria

On 01/14/2021, the European Commission authorized the marketing of Baqsimi® 3 mg (nasal glucagon), a powder medicine, ready to be used, in the treatment of severe hypoglycemia in adults, adolescents and children over four years of age with diabetes mellitus. Baqsimi® is the first and only nasal glucagon treatment available approved in the European Union (EU), and has been designed as a rescue treatment in cases of severe hypoglycemia, being absorbed passively into the ...

hrp0095p2-87 | Diabetes and Insulin | ESPE2022

100 years with insulin. Implementation of analogs and technology in our environment

Diez-Lopez Ignacio , Sarasua-Miranda Ainhoa , José Espina-Diez Maria

Almost 100 years ago, a major turning point in the life expectancy of people with diabetes around the world was reached with the discovery of insulin. In 1936, Hagedorn had the ingenious idea of combining insulin with a protein, protamine, and zinc and his NPH was used almost mainly in pediatrics until the end of 2003, when glargine U100 made its appearance.Objective: To evaluate the clinical experience in the incorporation of different ...

hrp0095p2-308 | Late Breaking | ESPE2022

Lal-D: Know it To Recognize it

Paglia Pamela , Valerio Giuliana , Ranucci Giusy , Rosaria Licenziati Maria

Introduction: Lysosomal Acid Lipase Deficiency (LAL-D) is a rare and systemic condition, secondary to LIPA gene mutations, responsible for lysosomal accumulation of cholesterol esters and triglycerides. Clinical manifestations are heterogeneous in terms of age of onset, severity and biochemical and radiological findings. Dyslipidemia, hepatomegaly and hepatosteatosis with hypertransaminasemia are the most common features. There is significant evidence of incre...

hrp0092fc3.3 | Multi-system Endocrine Disorders | ESPE2019

Variability in Drug Metabolizing Cytochrome P450 Activities Caused by Human Genetic Variations in NADPH Cytochrome P450 Oxidoreductase (POR)

Velazquez Maria Natalia Rojas , Parween Shaheena , Pandey Amit V

Background: A broad spectrum of human diseases, including abnormalities in steroidogenesis, are caused by mutations in the NADPH cytochrome P450 oxidoreductase (POR) (1-2). Cytochrome P450 proteins perform several reactions, including metabolism of steroids, drugs and other xenobiotics. Therefore, genetic variations in POR can impact many different metabolic pathways by changing the activities of cytochromes P450 (1). In 2004 the first human patients with defe...

hrp0092p1-279 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology (1) | ESPE2019

Gender Mender, or Defender: Understanding Decision Making in Aotearoa/New Zealand for People Born with a Variation in Sex Characteristics

Steers Denise , Ballantyne Angela , Stubbe Maria , Collings Sunny , Wiltshire Esko

People born with a variation in sex characteristics (VSC) face the challenge of having atypically sexed bodies. This quantitative study recruited 10 young adults with a VSC (14 to 24 years); 18 parents of children with a VSC; and 22 health professionals working in the VSC field. Interviews were semi structured, digitally recorded and transcribed. Using thematic analysis, we identified key themes regarding participants' experiences of health care decision-making. This study...

hrp0092p1-357 | Fat, Metabolism and Obesity (2) | ESPE2019

Evaluation of Body Composition and Resting Metabolic Rate in Adolescents with KS

Bespaliuk Daria , Chugunov Igor , Okorokov Pavel , Kareva Maria

Background: Klinefelter syndrome (KS) is a frequent anomaly of sex chromosomes, due to the presence of an extra X chromosome (one or more) in the karyotype 46, XY. This disease is characterized by hypergonadotropic hypogonadism and a high risk of developing disorders of carbohydrate and fat metabolism, despite the absence of a pronounced androgen deficiency in adolescents with KS. There are reports of changes in body composition in adolescents with KS even bef...

hrp0092p1-393 | Growth and Syndromes (to include Turner Syndrome) (2) | ESPE2019

Evaluation of Body Composition and Resting Metabolic Rate in Children with Growth Hormone Deficiency

Masueva Madina , Okorokov Pavel , Pankratova Maria , Yusipovich Alexander , Shiryaeva Tatiana

Background/Aims: It is known that growth hormone regulated metabolic processes, including lipid metabolism and the amount of adipose tissue. The purpose was to study metabolic rates at rest in children with growth hormone deficiency (GHD) and their relationship with lipid and hormone levels.Objective: To analyse the body composition and resting metabolic rate (RMR) among prepubertal children with GHD<p class="abstext...

hrp0092p2-9 | Adrenals and HPA Axis | ESPE2019

The Clinical Polymorphism and Variability of X-linked Adrenoleukodystrophy in One Russian Family

Sidorova Yuliya , Sozaeva Leila , Kareva Maria , Peterkova Valentina

Adrenoleukodystrophy is an X-linked, inherited metabolic disorder. Here, we present 3 clinical cases of different phenotypes with one mutation in ABCD1 gene in one family.Patient 1: At the age of 9 years, manifestation of neurological symptoms was observed, skin color changed, these symptoms progressed monthly. MRI of the brain showed 13 points on Loes scale.During the examination, the diagnosis of X-linke...